Pure Global AI
NCT05912244Recruiting

A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

A Phase II Study of IO102/IO103 and Nivolumab-relatlimab Fixed Dose Combination in Untreated, Unresectable Stage III/IV Melanoma
Memorial Sloan Kettering Cancer CenterPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Melanoma
Drug/Device/Intervention
IO102/IO103
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Memorial Sloan Kettering Cancer Center
Location
Basking Ridge,Middletown,Montvale,Commack,Harrison,New York,Uniondale, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Jun 09, 2023
End date
Jun 09, 2027
Enrollment
43 participants
Primary outcome

Overall Response Rate (ORR)

Summary

The researchers are doing this study to find out whether the study vaccines, IO102/IO103,
 given in combination with the standard-of-care drug combination, nivolumab and relatlimab, is
 a safe and effective treatment for people with untreated, unresectable melanoma.

ICD-10 classifications
Malignant melanoma of skinMelanoma in situ, unspecifiedMelanoma in situMelanoma and other malignant neoplasms of skinMalignant neoplasm: Malignant melanoma of skin, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05912244
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05912244 through Pure Global AI's free database. This Phase 2 trial is sponsored by Memorial Sloan Kettering Cancer Center and is currently Recruiting. The study focuses on Melanoma. Target enrollment is 43 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.